Get started
Author

Marion Bertho

Observed names: Bertho, Marion, M BERTHO, M. Bertho, Marion BERTHO
ORCID: 0000-0001-6992-9174
Observed ORCID: 0000-0001-6992-9174
OpenAlex ID: A5078335912
Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program
2021 · Marion Bertho, Julien Fraisse, et al. · Therapeutic Advances in Medical Oncology · 32
Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
2023 · D. Bello Roufai, A. Gonçalves, et al. · Oncogene · 23
PDF
Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors
2023 · Pauline Rottier, Angélique DA SILVA, et al. · Frontiers in Oncology · 17
PDF
A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer
2020 · Marion Bertho, Anne Patsouris, et al. · Expert Opinion on Drug Metabolism & Toxicology · 11
Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
2023 · D. Bello Roufai, A. Gonçalves, et al. · Oncogene · 3
PDF
Alpelisib and fulvestrant efficacy in HR-positive HER2-negative PIK3CA-mutant advanced breast cancer: Data from the French early access program.
2021 · Diana Bello, Alexandre Bertucci, et al. · Journal of Clinical Oncology · 2
Abstract P2-19-01: Impact of bone-only metastatic breast cancer on outcome in a real-life setting: A comprehensive analysis of 5,041 women from the ESME database
2020 · Marion Bertho, Julien Fraisse, et al. · Cancer Research
[Biliary peritonitis due to primary necrosis of the common bile duct--immediate reconstruction].
1963 · A MAREUGE, M BERTHO · PubMed
Works count: 15
Citation count: 88
H-index: 4
I10-index: 4
Year
Topic
Type